TP53 and colorectal cancer: In contrast, another study observed that targeting GSK3β by RNAi or pharmacological inhibitors resulted in p53-dependent induction of p21 and apoptosis in colorectal cancer cells harboring wild-type p53, thereby inhibiting tumor growth in xenograft mice models [123].